Moreover, our case indicates that ALK-rearranged NSCLC may possibly acquire resistance to crizotinib through the emergence of concurrent somatic mutations in both EGFR and KRAS genes. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.